TAVI Technology and Procedural Changes
|
|
|
- Dale Maximillian Walton
- 5 years ago
- Views:
Transcription
1 TCT AP 2013 Seoul, South Korea April, 2013 TAVI Technology and Procedural Changes Eberhard Grube MD, FACC, FSCAI University Hospital, Dept of Medicine II, Bonn, Germany Hospital Alemão Oswaldo Cruz, São Paulo, Brazil Stanford University, Palo Alto, California, USA
2 Eberhard Grube, MD Within the past 12 months, the presenter or their spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Physician Name Eberhard Grube, MD Company/Relationship Medtronic, CoreValve: C, SB, AB, OF Sadra Medical: E, C, SB, AB Direct Flow: C, SB, AB Mitralign: AB, SB, E Boston Scientific: C, SB, AB Biosensors: E, SB, C, AB Cordis: AB Abbott Vascular: AB Capella: SB, C, AB Valtech: E, SB, Claret: SB Key G Grant and or Research Support E Equity Interests S Salary, AB Advisory Board C Consulting fees, Honoraria R Royalty Income I Intellectual Property Rights SB Speaker s Bureau O Ownership OF Other Financial Benefits
3 Technology and Procedural Changes Current State: Positive Overall Therapy Outcomes Opportunities to Advance Outcomes Stroke Aortic Regurgitation and Paravalvular leak Vascular complications Conduction disturbances Future Innovation New Indications
4 Positive Survival is Being Consistently Achieved 1-Year Mortality p=0.68
5 Major Procedural Complications are Rare CoreValve ADVANCE Procedural Results
6 Remaining TAVI Challenges Procedure/Technique Technology Stroke AR and PVL Vascular Complications Balloon strategies Anti-coagulation mgmt Sizing Post-implant intervention (dilation, snare) Depth of Implant Alternative Access Embolic Protection Frame design Advanced Sealing Positioning, Recapture Lower profile Access specific delivery Coatings Conduction Disturbances Depth of Implant Balloon strategies Frame design Stable deployment with recapture
7 Technology and Procedural Changes Current State: Positive Overall Therapy Outcomes Opportunities to Advance Outcomes Stroke Aortic Regurgitation and Paravalvular leak Vascular complications Conduction disturbances Future Innovation, New Indications
8 Neuro-Imaging with TAVI JACC 2011 N=60 JACC 2010 N=30 JACC Int 2010 N=25 Circulation 2010 N=32 EJCTS 2011 N=80 Daneault et al., JACC 2011;58:
9 Embolic Material after TAVI
10
11 Anti-platelet therapy/anticoagulation in TAVI Therapeutic Procedure Intraprocedural therapy: - Aspirin 500mg - Clopidogrel 300/75mg - Heparin Open Questions Alternatives??? Aspirin only Prasugrel/Ticagrelor Bivalirudine Postprocedural therapy: - Aspirin 100mg - Clopidogrel 75mg - Oral anticoagulation (Afib) Duration??? 3 or 6 months Prasugrel/Ticagrelor Dabigatran/Rivaroxaban? LAA closure in Afib patients? No evidence-based recommendations!
12 Technology and Procedural Changes Current State: Positive Overall Therapy Outcomes Opportunities to Advance Outcomes Stroke Aortic Regurgitation and Paravalvular leak Vascular complications Conduction disturbances Future Innovation, New Indications
13 Moderate/severe paravalvular AR Grube, Circ, 2006 Leon, NEJM, 2010 Abdel-Wahab, Heart, 2011 Medtronic CoreValve Edwards-SAPIEN Tamburino, Circ, 2011 Smith, NEJM, 2011 Moat, JACC, 2011 Sinning, JACC, 2012 Gilard, NEJM, 2012 Vasa-Nicotera, JACC INT, 2012
14 Challenges Remain
15 Can we improve par? (balloon dilation, V-in-V, snare) Before Intervention After Intervention par grade
16 Can we improve par? (balloon dilation, V-in-V, snare) Pre- TAVI Immediately post TAVI Final TAVI
17 New Technologies to Further Reduce PVL Annular Sealing Optimized radial force Positioning arms Skirt design Optimal Positioning Stable Deployment Recapture capability Accessories (e.g. guidewire)
18 CoreValve Evolut R System with EnVeo R DCS Fully resheathable, repositionable, recapturable Evolut R Valve EnVeo R Delivery System Ability to recapture across all valve sizes InLine Sheath for 15F delivery profile Full annulus range mm
19 Technology and Procedural Changes Current State: Positive Overall Therapy Outcomes Opportunities to Advance Outcomes Stroke Aortic Regurgitation and Paravalvular leak Vascular complications Conduction disturbances Future Innovation, New Indications
20 Mortality and Major Vascular Complications PARTNER B TAVI patients Mortality (%) Major Vascular Complication (n=31) No Major Vascular Complication (n=148) P (log rank) = % 27.7% Months Complications & Adverse Events: Frequency, Timing, Causes and Impact on Short- and Long-Term Outcome; Webb; TCT, 2010.
21 Larger Sheath Size Can Contribute to Major Vascular Complications A Sheath to Femoral Artery Ratio (SFAR) 1.05 is a Predictor of both VARC Major Vascular Complications and 30-Day Mortality Sapien or Sapien XT (n = 102) CoreValve (n = 28)
22 Decreased Delivery System Profile to Reduce Major Vascular Complications InLine Sheath Eliminates Need for External Sheath Sheath-to-femoral artery ratio (SFAR) with the InLine Sheath is less than 1.00 for all valve sizes (23, 26, 29, and 31mm) in vessels down to 6mm in diameter Inner Diameter Becomes Effective Delivery Profile, resulting in 15FR delivery profile when using InLine Sheath Current 22 FR (OD) FR (OD) Future 18 FR (OD) 18FR 16FR 18FR CoreValve w/ 18Fr Cook Sheath Sapien XT w/ Edwards Sheath CoreValve Evolut R w/ InLine Sheath 1 Hayashida K., Lefevre T., Chevalier B.; et al. Transfemoral Aortic Valve Implantation; New Criteria to Predict Vascular Complications, J Am Coll Cardiol Intv
23 Technology and Procedural Changes Current State: Positive Overall Therapy Outcomes Opportunities to Advance Outcomes Stroke Aortic Regurgitation and Paravalvular leak Vascular complications Conduction disturbances Future Innovation, New Indications
24 Implant Depth Impacts Conduction Disturbances A lower (ventricular) position of the valve relative to the hinge point of the anterior mitral leaflet was associated with a higher incidence of new LBBB (35% vs. 0%, P =.029). Implanted Above 0% of patients developed LBBB Hinge Point of the Anterior Mitral Valve Implanted Below 35% of patients developed LBBB Gutierrez et al. Am Heart J 2009, (N=33)
25 Pilot study of 60 consecutive patients Procedural success: 96.7% (58 of 60 patients). A new pacemaker: 11.7% (7 of 60) of the patients without balloon pre-dilation 27.8% in a historical control group (n=126) Additionally the stroke rate was 5% in patients without balloon predilation as compared to 11.9% in the historical control group. TAVI without balloon pre-dilation seems to be feasible and should be investigated further in a larger trial. Grube et al., JACC CV Interv 2011;4:751-7
26 Relative Frequency (%) Direct TAVI: Bonn-Heidelberg Cohort 35 P = N = 310 patients P = Direct TAVI P = 0.97 P = Comb. Endpoint 30-day Mortality Stroke Pacemaker Sinning et al, DGK 2013
27 Reducing Post-TAVI Conduction Disturbance CoreValve Next Generation Systems optimize frame design and provide ability to recapture CoreValve Evolut frame Shorter valve with reduced angulation Less traumatic Inflow Crowns 10% Shorter Evolut R with EnVeo R DCS Stable, controlled release Recapturability
28 Technology and Procedural Changes Current State: Positive Overall Therapy Outcomes Opportunities to Advance Outcomes Stroke Aortic Regurgitation and Paravalvular leak Vascular complications Conduction disturbances Future Innovation, New Indications
29 CoreValve Evolut Innovation Pipeline Time CoreValve Evolut 23 mm 18FR System EnVeo 18FR Delivery System CoreValve Evolut Recaptureable with EnVeo R 23 mm 15 FR System CoreValve Evolut Recaptureable with EnVeo R 26/29/31 mm 15FR System Compatible with CoreValve 26/29/31 mm AccuTrak Delivery System 18 mm to 29 mm Annulus Size Range to Avoid Patient Prosthesis Mismatch These devices have NOT obtained CE Mark. They are not approved in the EU or the US for commercialization.
30 Minimizing TAVI Complications: Procedural Solutions 13F Profile Adaptive Sheath Nitinol technology expands and contracts Allows navigation of heavily calcified arteries Pre-Curved Guidewire Eliminates need for manual shaping of wire Variable wire stiffness throughout for ease of implantation and use
31 Potential for Expanded Indications Failed Bioprothesis Pure Aortic Insufficiency Bicuspid Valve
Eberhard Grube MD, FACC, FSCAI
3 rd TAVI Summit Seoul, August 9/10, 2013 Eberhard Grube MD, FACC, FSCAI University Hospital, Dept of Medicine II, Bonn, Germany y p, p,, y Hospital Alemão Oswaldo Cruz, São Paulo, Brazil Stanford University,
TAVI Implantation: Rapid Pacing, Pre and Post Dilatation
TAVI Summit 2012 Seoul, September 9, 2012 TAVI Implantation: Rapid Pacing, Pre and Post Dilatation Eberhard Grube, MD, FACC, FSCAI Medizinische i i Klinik ik und Polikinik II, University i Hospital Bonn,
Eberhard Grube MD, FACC, FSCAI
TAVI - Summit 2012 Seoul, September 8, 2012 Next Generation TAVI Systems Eberhard Grube MD, FACC, FSCAI University Hospital, Dept of Medicine II, Bonn, Germany Hospital Alemão Oswaldo Cruz, São Paulo,
Lotus Valve System for Transcatheter Aortic Valve Implantation/Replacement (TAVI/R) Evidence
X Congreso Coilegio Colombiano Santiago de Cali, 29-31 Octubre des 2014 Lotus Valve System for Transcatheter Aortic Valve Implantation/Replacement (TAVI/R) Evidence Eberhard Grube MD, FACC, FSCAI University
Transcatheter Aortic Valve Replacement with Evolut-R
Transcatheter Aortic Valve Replacement with Evolut-R Department of Transcatheter Heart Valves and 2 nd Cardiothoracic Surgery Clinic K. Spargias, M.Chrissoheris, A.Halapas, I. Nikolaou, S.Pattakos Disclosures
CoreValve Evolut R Technology review and Clinical Results. Paul TL Chiam
CoreValve Evolut R Technology review and Clinical Results Paul TL Chiam MBBS (S pore), MMed, MRCP (UK), FAMS FRCP (Edin), FESC (EU), FACC (USA), FSCAI (USA) Cardiologist Mount Elizabeth Hospital Singapore
TAVI Summit Eberhard Grube MD FACC, FSCAI Universitätsklinik Bonn, Medizinische Klinik und Poliklinik II, Bonn, Germany
TAVI Summit 2012 Seoul, September 8, 2012 TAVI Various Access Sites Eberhard Grube MD FACC, FSCAI Universitätsklinik Bonn, Medizinische Klinik und Poliklinik II, Bonn, Germany StanfordUniversity University,
Why Cerebral Protection after TAVR Will Become the Standard of Care
Vancouver, June 5 th, 2014 Why Cerebral Protection after TAVR Will Become the Standard of Care Eberhard Grube MD, FACC, FSCAI University Hospital, Dept of Medicine II, Bonn, Germany Stanford University,
Complicanze durante TAVI. Brambilla Nedy IRCCS Policlinico San Donato
Complicanze durante TAVI Brambilla Nedy IRCCS Policlinico San Donato 0 2 4 6 9 11 14 16 22 26 31 33 37 43 52 61 69 78 87 93 106 113 121 151 171 186 201 225 267 283 294 311 349 502 515 709 1007 Number of
Eberhard Grube, MD, FACC, FSCAI
TCT Asia Seoul, April 29, 2010 MDT / Core Valve Device Evolution, Technique and Clinical Trial Update Eberhard Grube, MD, FACC, FSCAI Intl. Heart Center Rhein-Ruhr, Essen, Germany Hospital Oswaldo Cruz
30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study
30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the Study Stephan Windecker Department of Cardiology Bern University Hospital - INSELSPITAL
A Thoughtful Synthesis of the TAVR Landscape: What s New, What s Needed and is There a Best-in-Class?
TVT Chicago Thursday 16th of June 2016 Session 1: TAVR 2016 Highlights and Controversies A Thoughtful Synthesis of the TAVR Landscape: What s New, What s Needed and is There a Best-in-Class? Ian T. Meredith
Progress In Transcatheter Aortic Valve Implantation
Progress In Transcatheter Aortic Valve Implantation Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia 4 th APCASH 8 th Sept 2013 Disclosure Statement
Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?
Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients? Didier TCHETCHE, MD. Clinique PASTEUR, Toulouse, France, Conflicts of interest: -Consultant for Edwards LifeSciences
Corrado Tamburino, MD, PhD
Paravalvular leak: acceptable or not Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular Department, Director Cardiology Division,
Update on the CoreValve Experience
TCT Asia Pacific April 22-24, 2009 Update on the CoreValve Experience Eberhard Grube HELIOS Klinikum, Germany Instituto Dante Pazzanese de Cardiología, São Paulo, Brazil Stanford University, Palo Alto,
Aortic Stenosis. TAVR available devices Ioannis Iakovou, MD, PhD
Aortic Stenosis. TAVR available devices Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Athens, Greece TAVI in 2018: Landscape TAVI is a Breakthrough Technology Dramatic
Istanbul Course of Interventional Cardiology Istanbul, June 11, 2011
Istanbul Course of Interventional Cardiology Istanbul, June 11, 2011 Within the past 12 months, the presenter or their spouse/partner have had a financial interest/arrangement or affiliation with the organization(s)
Aortic Stenosis. TAVR available devices Ioannis Iakovou, MD, PhD
Aortic Stenosis. TAVR available devices Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Athens, Greece Ομάδες εργασίας, Θεσσαλονίκη 2018 TAVI in 2018: Landscape TAVI is
TCTAP Seoul. TAVI: Incidence and. Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo, Brazil
TCTAP Seoul TAVI: Incidence and Treatment t of Procedural Complications Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo, Brazil University it Hospital Bonn, Germany Stanford
Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
Le TAVI pour tout le monde?
Le TAVI pour tout le monde? Thierry Lefèvre Institut Cardiovasculaire Paris Sud, Massy Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation or
Vascular complications of embolized core valve
Vascular complications of embolized core valve Suhail Dohad, MD FACC Director of Endovascular services, Interventional Cardiology Cardiovascular Research Foundation of Southern California, CVMG Director
TAVI: Transapical Procedures
Cardiology Update Davos TAVI: Transapical Procedures Volkmar Falk, MD University Hospital Zürich TA-AVI: antegrade, simple, safe The front door approach! Transapical TAVI Technical advantages of TA approach
Current Evidence in TAVI patients using ACURATE and LOTUS valves
Current Evidence in TAVI patients using ACURATE and LOTUS valves Giuseppe Tarantini, MD, PhD, FESC, Professor and Director of Interventional Cardiology University of Padua GISE President Potential conflicts
Which One is Better? CoreValve is Better!
TCT Asia-Pacific Seoul, April 26th, Korea Which One is Better? CoreValve is Better! Eberhard Grube MD, FACC, FSCAI Universitätsklinikum Bonn, Bonn, Germany Hospital Alemão Oswaldo Cruz, São Paulo, Brazil
Evolut R in bicuspid valve anatomies
Evolut R in bicuspid valve anatomies U. Gerckens MD University of Rostock, Germany Potential conflicts of interest Speaker's name: Ulrich Gerckens I have the following potential conflicts of interest to
Transcatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
3 rd TAVI Summit Seoul, August 9/10, 2013
3 rd TAVI Summit Seoul, August 9/10, 2013 Durability of the EW Sapien Valve and the MDT Core Valve Eberhard Grube MD, FACC, FSCAI University Hospital, Dept of Medicine II, Bonn, Germany Hospital Alemão
transcatheter heart valve: THV TAVI transcatheter aortic valve implantation
transcatheter heart valve: THV TAVI transcatheter aortic valve implantation Hideki OSHIMA 1. はじめに transcatheter heart valve: THV 1) transcatheter aortic valve implantation: TAVI transcatheter mitral valve
TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR
TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR Saibal Kar, MD, FACC, FAHA, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute, Cedars-Sinai
TAVI EN INSUFICIENCIA AORTICA
TAVI EN INSUFICIENCIA AORTICA Cesar Moris Profesor Cardiología Director Departamento del Corazón Hospital Universitario Central de Asturias Universidad de Oviedo OVIEDO -- ESPAÑA CONFLICTO DE INTERESES
How to manage TAVI related vascular complications. Paul TL Chiam MBBS, FRCP, FESC, FACC, FSCAI
How to manage TAVI related vascular complications Paul TL Chiam MBBS, FRCP, FESC, FACC, FSCAI Definition VARC-2 consensus statement Complications caused by: Wire Catheter Anything related to vascular access
Paravalvular Regurgitation is a Risk Factor Following TAVI
Paravalvular Regurgitation is a Risk Factor Following TAVI Philippe Pibarot, DVM, PhD, FACC, FESC, FASE Canada Research Chair in Valvular Heart Disease INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved
Transcatheter Aortic Valve Replacement Symptomatic Aortic Stenosis Asymptomatic Juan Crestanello, MD Interim Director, Division of Cardiac Surgery Associate Professor Division of Cardiac Surgery The Ohio
SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes
SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes Howard C. Herrmann, MD on behalf of The PARTNER II Trial
SAPIEN 3 Sizing Considerations:
SAPIEN 3 Sizing Considerations: Oversizing, Undersizing, or Volume reduction? John Webb MD St Paul s Hospital University of British Columbia Vancouver Disclosure Statement of Financial Interest Within
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
Trans Catheter Aortic Valve Replacement
Trans Catheter Aortic Valve Replacement Satish K Surabhi, MD,FACC,FSCAI Medical Director, Cardiac Cath Labs AnMed Health Heart and Vascular Care No financial conflict of interest related to this talk Will
PVL Assessment. Is paravalvular regurgitation after TAVR still an important consideration in 2018?
Joint Meeting 1 Aortic and Mitral Club Chairpersons: S.Adamopoulos, M. Vavuranakis, L. Michalis, P. Nihoyannopoulos PVL Assessment. Is paravalvular regurgitation after TAVR still an important consideration
Jonathon Leipsic MD FRCPC FSCCT. Vice Chairman of Radiology University of British Columbia. Disclosures
Jonathon Leipsic MD FRCPC FSCCT Vice Chairman of Radiology University of British Columbia Disclosures Speaker s bureau: GE Healthcare and Edwards LifeSciences Grant Support- CIHR, GE Healthcare Advisory
e Corrado Tamburino, MD, PhD
Transcatheter Aortic Valve Implantation Stroke: etiology ogy and prevention e Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular
Optimal Techniques for Obtaining Large Caliber Arterial Access
Optimal Techniques for Obtaining Large Caliber Arterial Access Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia APCASH 11 October 2014 Disclosure Statement
The Medtronic Core Valve System Direct Aortic Approch
3 rd TAVI Summit Seoul, August 9/10, 2013 The Medtronic Core Valve System Direct Aortic Approch Eberhard Grube MD, FACC, FSCAI Michael Reardon MD Michael Reardon MD Michael J. Reardon, M.D. Senior Member
TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre
TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre Disclosure St. Jude Medical: Consultant and Proctor Edwards Lifesciences: Proctor Medtronic: Research
TAVR: Review of the Robust Data from Randomized Trials
TAVR: Review of the Robust Data from Randomized Trials Nicholas J. Ruggiero II, MD,FACP, FACC, FSCAI, FSVM, FCPP Director, Structural Heart Disease and Non-Coronary Interventions Director, Jefferson Heart
Echo Assessment Pre-TAVI
Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial Interest /arrangement or affiliation with the organization(s) listed below Echocardiographic
EVOLUT R FORWARD 30-DAY OUTCOMES PRESENTED AT THE TCT ANNUAL MEETING OCTOBER 31, 2016
EVOLUT R FORWARD 30-DAY OUTCOMES PRESENTED AT THE TCT ANNUAL MEETING OCTOBER 31, 2016 OBJECTIVE/PRIMARY ENDPOINT FORWARD is a multicenter, prospective, single-arm, observational post-market study to evaluate
Development of a TMVR Device Challenge to Innovators
Development of a TMVR Device Challenge to Innovators Eberhard Grube MD, FACC, FSCAI, FAPSIC University Bonn, Heart Center, Bonn, Germany Stanford Universuty, School of Medicine, Palo Alto, CA Disclosure
2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route
Transcatheter Aortic Valve Implantation Asian perspective Speakers s name: Paul Chiam Paul TL Chiam MBBS, MRCP, FACC I have the following potential conflicts of interest to report: NONE Consultant National
Transcatheter aortic valve implantation for severe aortic valve stenosis with the ACURATE neo2 valve system: 30-day safety and performance outcomes
All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions
(EU), FACC (USA), FSCAI (USA)
How to reduce vascular complications of TAVI Paul TL Chiam MBBS (S pore), MMed, MRCP (UK), FAMS FRCP (Edin), FESC (EU), FACC (USA), FSCAI (USA) Cardiologist Mount Elizabeth Hospital Singapore Definition
Role of Embolic Protection during TAVR
Role of Embolic Protection during TAVR Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac Catheterization Laboratories Disclosure Co PI for Sentinel Trial
TAVR for low-risk patients in 2017: not so fast.
TAVR for low-risk patients in 2017: not so fast. Enrico Ferrari, MD, FETCS Cardiac Surgery Department Cardiocentro Ticino Foundation Lugano, Switzerland Conflicts of Interest Consultant and proctor for
TAVR: Current Valve Types. Patient Selection
TAVR: Current Valve Types. Patient Selection Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital
Mitral Programme Update
Direct Flow Medical Innovations in the Aortic and Mitral Programmes Mitral Programme Update Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy Potential conflicts
TAVI limitations for low risk patients
TAVI limitations for low risk patients Dr. T. Modine / P. Lancellotti MD, PhD, MBA CHRU de Lille, France Potential conflicts of interest Speaker's name: Thomas Modine I have the following potential conflicts
A review of the complications associated with Transcatheter Aortic Valve Implantation.
A review of the complications associated with Transcatheter Aortic Valve Implantation. Dr Conor McQuillan Transcatheter Aortic Valve Implantation (TAVI) has become the standard of care for treating elderly,
Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison
Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison Mauri, V. et al.: Circ Cardiovasc Interv. 2017;10:e005013 All trademarks are the property
TAVI: Present and Future Perspective
TAVI: Present and Future Perspective Igor F. Palacios, M.D. Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School Percutaneous transcatheter
Pacemaker rates Second generation TAVI Devices
Pacemaker rates Second generation TAVI Devices Florian Krackhardt, M.D. Department of Cardiology Charité Campus Virchow-Klinikum University Hospital Berlin, Germany TAVI The future s looking very positive
TAVI in Korea, How to Avoid Conduction
TAVI in Korea, How to Avoid Conduction Disturbance after CoreValve Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul,
Current Controversies. Subclinical and clinical valve thrombosis
Chapter 19: Current controversies, ongoing trials, new valves, and future directions Sukhdeep S. Basra, MD, MPH, Michael J. Mack, MD The Heart Hospital Baylor Plano, Texas Transcatheter Aortic Valve Replacement
CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
TAVR SPRING 2017 The evolution of TAVR
TAVR SPRING 2017 The evolution of TAVR Matthew Johnson, MD Disclosers None Evolution of the Balloon- Expandable Transcatheter Valves Cribier 2002 SAPIEN 2006 SAPIEN XT 2009 SAPIEN 3 2013 * Sheath compatibility
An Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.
An Update on the Edwards TAVR Results Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. Luke s Hospital Disclosures On the speaker s bureau for Endologix, TriVascular,
Andrzej Ochala, MD Medical University of Silesia, Katowice, Poland
Andrzej Ochala, MD Medical University of Silesia, Katowice, Poland Bicuspid aortic valve o Most common congenital heart disease in adults (1% - 2%) o AS is the most common complication of BAV o Patophysiology
10 mins. Martin B. Leon, MD. Columbia University Medical Center Cardiovascular Research Foundation New York City
10 mins Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New York City Tuesday, November 1, 2016 Disclosure Statement of Financial Interest TCT 2016 Washington,
Transcatheter aortic valves in aortic regurgitation Gry Dahle Dept of Cardiothoracic- and vascular surgery Rikshospitalet, Oslo University Hospital,
Transcatheter aortic valves in aortic regurgitation Gry Dahle Dept of Cardiothoracic- and vascular surgery Rikshospitalet, Oslo University Hospital, Oslo, Norway Aortic regurgitation Prevalence in Framingham
Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute
Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries
Aortic stenosis (AS) remains the most common
Sapien Valve: Past, Present, and Future A look at how the Sapien family of valves continues to evolve to treat a range of patients seeking transcatheter aortic valve replacement. BY RAVINDER SINGH RAO,
Comments restricted to Sapien and Corevalve 9/12/2016. Disclosures: Core Lab contracts with Edwards Lifesciences, Middlepeak, Medtronic
Para-ValvularRegurgitation post TAVR: Predict, Prevent, Quantitate, Manage Linda D. Gillam, MD, MPH, FACC, FASE Chair, Department of Cardiovascular Medicine Morristown Medical Center/Atlantic Health System
Index. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablation, of mitral leaflets, 80 Accucinch Annuloplasty system, for mitral regurgitation, 79, 94 95 Accutrak delivery system, for CoreValve
Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D.
Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D. Professor, Thoracic and Cardiovascular Surgery University of Florida klodell@surgery.ufl.edu Disclosures
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000
How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min
2016 ASE State of the Art Echocardiography Course Tucson, AZ How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, 2016 11:00 11:25 PM 25 min 1 M U H A M E D S A R I Ć, M D, P H D
Mild paravalvular regurgitation is not an independent predictor of mortality following TAVI
Mild paravalvular regurgitation is not an independent predictor of mortality following TAVI Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE Canada Research Chair in Valvular Heart Diseases INSTITUT UNIVERSITAIRE
2/10/2012. The Role of Multimodality Imaging in Percutaneous Valve Interventions. This is truly a TEAM work. Overview. Overview
The Role of Multimodality Imaging in Percutaneous Valve Interventions João L. Cavalcante, MD Advanced Cardiovascular Imaging Cleveland Clinic 02/11/2012 Disclosures: None Movement from surgery to transcatheter
Ian T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia
Two-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III On Behalf of the CoreValve US Clinical Investigators
Aortic valve implantation using the femoral and apical access: a single center experience.
Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany
Prof. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation
Prof. Dr. Thomas Walther TAVI in ascending aorta / aortic root dilatation nn AorticStenosis - Guidelines TAVI and aortic aneurysm? Few data published. EJCTS 2014;46:228-33 TAVI and aortic aneurysm? Few
Strokes After TAVR. Ioannis Iakovou, MD, PhD. Interventional Cardiology Onassis Cardiac Surgery Center
Strokes After TAVR Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Strokes After TAVR How common is stroke after TAVR Is it increasing? Is it more with TF vs TA? Is it
Transcatheter Aortic Valve Implantation Present Status and Perspectives
Transcatheter Aortic Valve Implantation Present Status and Perspectives Angioplasty Summit TCTAP 2010 Alain Cribier, MD University of Rouen, France Transcatheter Aortic Valve Implantation has entered the
TAVI: Nouveaux Horizons
TAVI: Nouveaux Horizons EUAPI580i 432HQ14NP02353 Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Objectifs Les recommandations Le TAVI en chiffre La
The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center
The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health Adam J. Saltzman, MD Cardiovascular Care Center Southcoast Health Disclosures Edwards Lifesciences: speaking honorarium Outline
Update on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center
Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock
Transcatheter Aortic Valve Implantation Management of risks and complications
Transcatheter Aortic Valve Implantation Management of risks and complications TAVI Summit, Seoul, Korea, Spetember 3rd, 2011 Alain Cribier University of Rouen, France Complications of TAVI Depending on
How to manage device embolization?
How to manage device embolization? Swiss Fellow Course Interventional Cardiology Amir-Ali Fassa Hôpital de La Tour Meyrin, Geneva Coronary interventions: Definitions Stent loss: stent dislodgment from
Prevention and Management of Vascular Complications Related to Transcatheter Aortic Valve Implantation
Prevention and Management of Vascular Complications Related to Transcatheter Aortic Valve Implantation Marco Roffi Division of Cardiology University Hospital Geneva, Switzerland Disclosure Speaker name:...marco
Image Assistance in TAVI Why CT? Won-Jang Kim, MD, PhD Clinical Assistant Professor of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea
Image Assistance in TAVI Why CT? Won-Jang Kim, MD, PhD Clinical Assistant Professor of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea Major Uses of CT in TAVI Ileofemoral Patient Arterial
Update on Transcatheter Mitral Valve Repair and Replacment
Update on Transcatheter Mitral Valve Repair and Replacment Vinod H. Thourani, MD Professor of Surgery Chair, Department of Cardiac Surgery Medstar Heart and Vascular Washington Hospital Center Georgetown
PM indications before and after TAVI
PM indications before and after TAVI PD Dr. med. Stefan Toggweiler LA Herzzentrum Leiter interventionelle Klappentherapie Luzerner Kantonsspital 6000 Luzern Agenda Basics Predictors for PPM implantation
1-YEAR OUTCOMES FROM JOHN WEBB, MD
1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013
Imaging in TAVI Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013 Research grants: Medtronic, Biotronik, Boston Scientific, St Jude, BMS imaging, GE Healthcare,
TAVI: FUTURE DEVELOPMENTS
4 th Aortic Live Symposium TAVI: FUTURE DEVELOPMENTS Volkmar Falk Disclosure Speaker name: Volkmar Falk... I have the following potential conflicts of interest to report: Consulting: Aesculap Employment
Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee
Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee Queen Elizabeth Hospital, Hong Kong President, HKSTENT APCASH 2013 SJ Park TAVI Summit 2013
Emerging Transcatheter Aortic Valve Technologies
East Meets West: Emerging Transcatheter Aortic Valve Technologies Emerging valve systems and iterative technologies from around the world and how they could shape global practice going forward. BY FEDERICO